<p>Bayer AG has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its MEDRAD® Centargo multi-patient CT injector system. The clearance expands the system’s compatibility to include single-dose vials in addition to Imaging Bulk Package presentations for several leading CT contrast agents: Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol), and now Visipaque™ (iodixanol). This development offers radiology suites increased flexibility in managing contrast agent consumption and waste, particularly for those transitioning to bulk contrast use. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201711198) on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

BAYZF

BAYRY

<p>Bayer AG has received FDA clearance for its MEDRAD Centargo CT injector system, expanding its compatibility to include single-dose vials for several CT contrast agents. This development enhances flexibility in radiology suites for managing contrast agent consumption and waste.</p>

Bayer Wins FDA Clearance to Expand MEDRAD Centargo CT Injector Contrast Agent Options